Australia's Telix Pharmaceuticals slides on sequential fall in quarterly revenue

By Reuters News

** Shares of Australia's Telix Pharmaceuticals TLX.AX fall 7.6% to A$14.56, hitting their lowest level since August 5

** The radiopharmaceutical company reported a 1% sequential fall in group revenue for the third quarter to $235 million, though this was an increase compared to last year

** Revenue from its biggest segment precision medicine was stagnant, compared with previous quarter at $201 million

** "We expect some seasonality and our 2H forecasts imply 4Q will rise again, against the backdrop of a maturing market in existing indications," says Citi

** Telix stock up over 30%, YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.